First Trust Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.7M | Buy |
90,893
+10,492
| +13% | +$2.47M | 0.02% | 835 |
|
|
2026
Q1 | $16.1M | Buy |
80,401
+11,181
| +16% | +$2.21M | 0.01% | 931 |
|
|
2025
Q4 | $13.1M | Buy |
69,220
+17,532
| +34% | +$3.37M | 0.01% | 1003 |
|
|
2025
Q3 | $9.16M | Buy |
51,688
+2,848
| +6% | +$423K | 0.01% | 1123 |
|
|
2025
Q2 | $5.55M | Buy |
48,840
+16,570
| +51% | +$1.77M | ﹤0.01% | 1312 |
|
|
2025
Q1 | $3.39M | Sell |
32,270
-1,056
| -3% | -$119K | ﹤0.01% | 1518 |
|
|
2024
Q4 | $3.57M | Sell |
33,326
-2,011
| -6% | -$227K | ﹤0.01% | 1549 |
|
|
2024
Q3 | $3.54M | Buy |
35,337
+3,502
| +11% | +$353K | ﹤0.01% | 1497 |
|
|
2024
Q2 | $2.68M | Buy |
31,835
+11,110
| +54% | +$884K | ﹤0.01% | 1570 |
|
|
2024
Q1 | $1.51M | Sell |
20,725
-492
| -2% | -$36.3K | ﹤0.01% | 1846 |
|
|
2023
Q4 | $1.52M | Buy |
21,217
+3,262
| +18% | +$193K | ﹤0.01% | 1836 |
|
|
2023
Q3 | $1.08M | Buy |
+17,955
| New | +$1.18M | ﹤0.01% | 1938 |
|
|
2023
Q2 | – | Sell |
-16,955
| Closed | -$1.25M | – | 2405 |
|
|
2023
Q1 | $1.25M | Buy |
16,955
+12,677
| +296% | +$901K | ﹤0.01% | 1899 |
|
|
2022
Q4 | $286K | Sell |
4,278
-13,353
| -76% | -$868K | ﹤0.01% | 2320 |
|
|
2022
Q3 | $947K | Sell |
17,631
-4,542
| -20% | -$267K | ﹤0.01% | 2018 |
|
|
2022
Q2 | $1.23M | Buy |
22,173
+9,431
| +74% | +$535K | ﹤0.01% | 1905 |
|
|
2022
Q1 | $894K | Buy |
12,742
+5,897
| +86% | +$428K | ﹤0.01% | 2080 |
|
|
2021
Q4 | $660K | Sell |
6,845
-13,271
| -66% | -$1.23M | ﹤0.01% | 2208 |
|
|
2021
Q3 | $1.75M | Sell |
20,116
-31,382
| -61% | -$2.43M | ﹤0.01% | 1819 |
|
|
2021
Q2 | $4.21M | Buy |
+51,498
| New | +$4.28M | ﹤0.01% | 1454 |
|
|
2021
Q1 | – | Sell |
-9,753
| Closed | -$605K | – | 2435 |
|
|
2020
Q4 | $605K | Sell |
9,753
-21,323
| -69% | -$1.22M | ﹤0.01% | 2070 |
|
|
2020
Q3 | $1.85M | Buy |
+31,076
| New | +$2.12M | ﹤0.01% | 1393 |
|
|
2019
Q1 | – | Sell |
-32,903
| Closed | -$2.79M | – | 2434 |
|
|
2018
Q4 | $2.79M | Sell |
32,903
-13,193
| -29% | -$1.41M | 0.01% | 1283 |
|
|
2018
Q3 | $7.89M | Buy |
46,096
+9,612
| +26% | +$1.45M | 0.01% | 912 |
|
|
2018
Q2 | $4.71M | Buy |
36,484
+16,378
| +81% | +$1.83M | 0.01% | 1126 |
|
|
2018
Q1 | $2.07M | Buy |
20,106
+48
| +0.2% | +$4.75K | ﹤0.01% | 1449 |
|
|
2017
Q4 | $1.71M | Buy |
20,058
+976
| +5% | +$84.6K | ﹤0.01% | 1605 |
|
|
2017
Q3 | $1.62M | Buy |
19,082
+12,157
| +176% | +$963K | ﹤0.01% | 1615 |
|
|
2017
Q2 | $524K | Buy |
+6,925
| New | +$484K | ﹤0.01% | 2045 |
|
|
2016
Q4 | – | Sell |
-34,227
| Closed | -$2.18M | – | 2469 |
|
|
2016
Q3 | $2.18M | Buy |
34,227
+7,192
| +27% | +$528K | 0.01% | 1287 |
|
|
2016
Q2 | $2.01M | Sell |
27,035
-5,201
| -16% | -$386K | 0.01% | 1311 |
|
|
2016
Q1 | $2.15M | Sell |
32,236
-398
| -1% | -$24.2K | 0.01% | 1265 |
|
|
2015
Q4 | $2.21M | Sell |
32,634
-20,411
| -38% | -$1.26M | 0.01% | 1337 |
|
|
2015
Q3 | $2.83M | Sell |
53,045
-4,807
| -8% | -$292K | 0.01% | 1202 |
|
|
2015
Q2 | $3.64M | Buy |
+57,852
| New | +$3.16M | 0.01% | 1175 |
|
|
2014
Q4 | – | Sell |
-39,849
| Closed | -$1.17M | – | 2280 |
|
|
2014
Q3 | $1.17M | Sell |
39,849
-18,787
| -32% | -$624K | ﹤0.01% | 1636 |
|
|
2014
Q2 | $2.28M | Sell |
58,636
-3,312
| -5% | -$134K | 0.01% | 1293 |
|
|
2014
Q1 | $2.6M | Buy |
+61,948
| New | +$2.58M | 0.01% | 1252 |
|
Other funds holding LGND
JT
CAM
First Trust Advisors's LGND Position: Q2 2026 in Review
First Trust Advisors increased its Ligand Pharmaceuticals (LGND) stake by 13% in Q2 2026, buying an estimated $2.47M and bringing the position to 90,893 shares worth $28.7M. The position accounts for 0.02% of the portfolio, ranked #835.
First Trust Advisors first reported a position in LGND in Q1 2014 and has held it in 38 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- First Trust Advisors held 90,893 shares of Ligand Pharmaceuticals worth $28.7M as of Q2 2026.
- First Trust Advisors bought 10,492 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.47M.
- Ligand Pharmaceuticals made up 0.02% of First Trust Advisors's portfolio in Q2 2026, its #835 holding.
- First Trust Advisors first reported a position in Ligand Pharmaceuticals in Q1 2014 and has held it in 38 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.